The Technical Analyst
ProShares UltraShort [BIS]
Exchange: NASDAQ
ProShares UltraShort Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.44% $20.58
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.04 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 0.148 mill |
| Avg Daily Volume: | 0.0207 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 14.70 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 17.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 20.18 - 21.00 ( +/- 2.00%) |
| ATR Model: 14 days |
Forecast:
16:00 - $20.59
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $20.59
Forecast 2: 16:00 - $20.59
Forecast 3: 16:00 - $20.59
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $20.58 (2.44% ) |
| Volume | 0.0084 mill |
| Avg. Vol. | 0.0207 mill |
| % of Avg. Vol | 40.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BIS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BIS
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Latest News
2023-06-26 09:01:05 - Zacks Investment Research
Best Inverse/Leveraged ETFs of Last Week
Wall Street gave a muted performance last week as the S&P 500 and the Nasdaq snapped the prolonged winning streak.
2022-12-05 13:58:37 - ETF Trends
3 ETFs in “Oversold” Territory to Start the Week
Technical analysis can tell investors a lot about both stocks and ETFs, including when some might have been overbought, or even oversold.
2022-10-10 08:17:09 - Zacks Investment Research
2 ETFs to Watch for Outsized Volume on Internet & Inverse Leveraged Biotech
2022-08-08 18:12:55 - Seeking Alpha
Purchase Levels Of 31 Short ETFs Signal Bear Market Bottom (Technical Analysis)
We are bearish on all American bear market ETFs. Measuring the purchase levels of short ETFs replaces the old, odd lot and total short selling indicators so popular in the 1960s, 70s and 80s.
2022-01-25 13:53:36 - ETF Trends
Cap-Weighting Crucial When Indexing Biotech
The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in development, hasn't received FDA approval, or hasn't been in the market long enough to establish a proven track record.
2020-06-29 14:00:04 - https://born2invest.com
The biotech sector as a safe bet for investments during the crisis
Biotechnology companies have many growth levers and are to be favored for their defensive qualities, in the context of the health and economic crisis.
2020-06-25 21:25:02 - https://www.marketscreener.com
Health Care Up On Biotech Demand -- Health Care Roundup | MarketScreener
2020-06-24 21:02:01 - https://www.marketscreener.com
Health Care Down, But Not By Much, Amid Defensive Bias -- Health Care Roundup
2020-06-24 10:49:00 - https://www.fool.com
2 Biotech Stocks With Major Incoming Catalysts | The Motley Fool
While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.
2020-03-16 19:52:03 - SEEKINGALPHA
ING's Latest Economic Views And Forecasts
Our gut feeling is that this will not be the last update. US: We are penciling in an 8.0% annualised 2Q20 GDP decline. Europe: Bund yields will likely continue